SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR

15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2015

 

Prana Biotechnology Limited

(Name of Registrant)

 

Level 2, 369 Royal Parade Parkville  Victoria  3052 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x                   Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ¨                      No x 

 

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____

 

This Form 6-K is being incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-199783) and Form S-8 (File No. 333-153669).

 

 

 

 

PRANA BIOTECHNOLOGY LIMITED

 

6-K Items

 

1.

Results of annual general meeting

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

  PRANA BIOTECHNOLOGY LIMITED
    (Registrant)
     
     
  By: /s/ Geoffrey Kempler  
    Geoffrey Kempler,
    Executive Chairman

  

November 13, 2015

 

 

 

 

 

 

COMPANY ANNOUNCEMENT

(ASX: PBT)

 

RESULTS OF ANNUAL GENERAL MEETING

 

 

Friday, 13th November 2015

 

The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried on a show of hands.

 

In accordance with ASX Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following information is provided in relation to the proxy votes received for each resolution considered by Members of the Company at the Annual General Meeting held today at 09.30am.

 

  Resolutions For Against Abstain Proxy's Discretion* Total Valid Proxies Received For Percentage
1 Adoption of Remuneration Report 38,159,479 8,274,152 1,711,270 2,559,018 50,703,919 83.11%
2 Re-election of Director - Dr George Mihaly 59,205,074 4,635,311 1,926,111 2,778,889 68,545,385 93.04%
3 Ratification of previously issued securities - ATM 59,663,653 5,437,981 664,867 2,778,884 68,545,385 91.99%
4 Approval to refresh employee share plan 40,574,805 7,112,428 675,968 2,552,518 50,915,719 85.84%
5 Approval of 10% Placement Issue 57,849,891 6,727,778 1,044,832 2,922,884 68,545,385 90.03%

 

*The Chairman voted undirected proxies in his control in favour of all resolutions.
**Note: Resolutions 1 and 5 are special resolutions and required 75% approval to be passed. This threshold has been achieved and both resolutions passed.

 

On behalf of the Board

Phillip Hains

Company Secretary

Prana Biotechnology Limited

 

 

 

Suite 1, 1233 High Street Armadale

Victoria Australia 3143

 

 

Page 1 of 1

 

Telephone: 61 3 9824 5254

Facsimile: 61 3 9822 7735